MagForce AG Publishes First Quarterly Shareholder Letter

Berlin, Germany, July 24, 2013 – MagForce AG (Frankfurt, Xetra: MF6), a leading medical device company in the area of nanotechnology with a focus on oncology, published today its first “Shareholder Letter”.

Subsequently, such shareholder letters shall be published quarterly in order to keep shareholders well informed about the ongoing developments and progress.

The shareholder letter can be downloaded here:

Key points are

- Personal introduction of Dr. Ben Lipps, designated CEO and Chairman of the Management Board
- Focus on recurrent Glioblastoma Multiform Cancer (GBM) and Prostate Cancer
- Details to GBM post-marketing study
- Search for strategic partners in Emerging Markets.

About MagForce AG
MagForce AG is a leading medical device company in the field of nanomedicine in oncology, listed in the entry standard (MF6). The Company's proprietary, NanoTherm® therapy, enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles. NanoTherm®, NanoPlan®, and NanoActivator™ are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm®, NanoPlan®, and NanoActivator™ are trademarks of MagForce AG in selected countries. For more information, please visit www.magforce.com.

Disclaimer
This release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects", "aims", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will". Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated.